Investing.com — Aligos Therapeutics Inc (ALGS)股价已触及52周低点，跌至6.71美元， InvestingPro ...

近日，厦门特宝生物工程股份有限公司（简称“特宝生物”）发布了2024年年度报告，报告显示公司实现营收28.17亿元，同比增长34.13%；归属于上市公司股东的净利润达到8.28亿元，同比增长49%。

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently ...

对于营收和净利双增长的原因，特宝生物表示，报告期内，公司主业稳健向好，尤其是随着乙肝临床治愈研究的不断深入，公司产品派格宾作为慢性乙肝抗病毒治疗的一线用药，进一步得到专家和患者的认可，产品持续放量，带动经营业绩实现较大增长。

Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class ...

EDT Aligos Therapeutics (ALGS) files to sell 6.25M shares of common stock for holdersLight Up your Portfolio with Spark:Easily identify ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...

特宝生物供图全球首个Y型40kD聚乙二醇干扰素-2b注射液、国家1类生物制品拓培非格司亭注射液纵览已上市产品和研发管线，人们不难发现，特宝生物一直深耕病毒性肝炎、恶性肿瘤等免疫相关重大疾病治疗领域。

The live webcast can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, ...